sponsored
PatientsVille.com Logo

PatientsVille

ZOCOR Medical Research Studies

Up-to-date List of ZOCOR Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest ZOCOR Medical Research Studies

Rank Status Study
1 Recruiting Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: Prostate Carcinoma
Interventions: Drug: Metformin;   Drug: Simvastatin
Outcome Measures: Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.;   Time to protocol-specified event for men treated with the combination of metformin plus simvastatin.;   Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin.;   Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
2 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
Outcome Measures: Safety of simvastatin in the treatment of LAM-S and LAM-TS patients on a stable (for at least 3 months) dose of sirolimus or everolimus.;   FEV1, FVC, DLCO, VEGF-D, and QOL; signs of clinical benefit.
3 Not yet recruiting Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Conditions: Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
Outcome Measures: Change in echocardiographic Global Longitudinal Strain (GLS);   Number of participants with adverse events as a measure of safety and tolerability;   Recurrence free survival (RFS) with concurrent simvastatin
4 Unknown  Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: Simvastatin
Outcome Measure: Progression free survival
5 Recruiting Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia
Interventions: Drug: Fenofibrate;   Drug: Simvastatin
Outcome Measures: Percentage change from baseline in triglycerides (TG) at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12;   Percentage changes from baseline in apoB/apoA1 ratio at week 12;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12;   Percentage changes from baseline in uric acid at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52;   Percentage changes from baseline in apoB/apoA1 ratio at week 52;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52;   Percentage changes from baseline in uric acid at week 52
6 Recruiting The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Condition: Asthma
Interventions: Drug: Simvastatin;   Drug: B1-6-12
Outcome Measures: Sputum eosinophils;   Phosphorylated p38 MAPK in sputum cells
7 Recruiting Stroke Treatment With Acute Reperfusion and Simvastatin
Condition: Stroke, Acute
Intervention: Drug: Simvastatin
Outcome Measures: The primary outcome of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.;   The secondary outcome of this study is to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.
8 Recruiting Simvastatin Addition for Patients With Recent-onset Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder;   Psychosis NOS
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Change in Positive And Negative Syndrome Scale (PANSS) total score;   Change in PANSS positive, negative and general psychopathology scale scores;   Change in Global Assessment of functioning scale (GAF) score;   Change in cognitive functioning;   Presence and severity of metabolic syndrome;   Change in presence and severity of movement disorders using validated scales
9 Recruiting Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
Condition: Rhinosinusitis
Intervention: Drug: SIMVASTATIN
Outcome Measures: Sino-Nasal symptomatology;   Bacterial culture;   Assessemt of liver and kidney functions;   RNA measurement of inflammatory biomarkers;   Sinus-Specific Quality of Life (22 questions Sino-nasal outcome test; SNOT-22);   Aspect of sinus mucosa aspect assessed by sinus endoscopy
10 Recruiting Effects of Simvastatin on Biomarkers
Condition: Alzheimer's Disease
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Cerebral Spinal Fluid Biomarker measurements;   Measures of inflammation or oxidative stress in cerebral spinal fluid.
11 Not yet recruiting The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia
Condition: Choroideremia
Intervention: Drug: Simvastatin
Outcome Measures: Full-field scotopic threshold;   Microperimetry, OCT, fundus autofluorescence, ERG, VA
12 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
Outcome Measures: the simvastatin can alleviate pulmonary hypertension;   pulmonary pressure;   simvastatin can highten the perioperative and long term survaval rate and the living quality
13 Recruiting Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Simvastatin
Outcome Measures: Vaso-occlusive pain events;   Correlation of plasma biomarkers with clinical measures of vaso-occlusive pain;   Clinical safety of simvastatin
14 Unknown  Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.
Conditions: Diabetes Mellitus;   Hypertension
Interventions: Drug: atrorvastatin 10mg;   Drug: simvastatin 40mg
Outcome Measures: Reduction in oxLDL levels;   Reduction in plasma malondialdehydes and urine isoprostanes;   Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor
15 Unknown  Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)
Conditions: Dyslipidemia;   Atherosclerosis
Interventions: Drug: simvastatin;   Drug: Nicotinic Acid
Outcome Measures: change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE);   changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a).
16 Recruiting Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Condition: Bipolar Disorder
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measure: Change in MADRS (4 weeks)
17 Unknown  Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Conditions: Cystic Fibrosis;   Anti Inflammatory Non-Steroidal;   Neutrophils
Interventions: Drug: Pioglitazone;   Drug: Simvastatin;   Drug: Ibuprofen
Outcome Measure: Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique
18 Recruiting Simvastatin for mTBI
Condition: TBI-Traumatic Brain Injury
Interventions: Drug: simvastatin;   Drug: placebo
Outcome Measures: cerebrospinal fluid (CSF) tau concentration;   Concentration of cerebrospinal fluid (CSF) Brain-derived neurotrophic factor (BDNF)
19 Recruiting Sarilumab Effect on the Pharmacokinetics of Simvastatin
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Drug: simvastatin
Outcome Measures: Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for simvastatin;   Assessment of PK parameters - maximum concentration (Cmax), time to maximum concentration (tmax), and terminal half-life associated with the terminal slope (t1/2z) for simvastatin;   Assessment of PK parameters - Cmax, AUClast, AUC, tmax, t1/2z for simvastatin acid;   Number of participants with adverse events
20 Recruiting Simvastatin Effect on Radiation Therapy of Brain Metastases
Condition: Brain Metastases
Interventions: Drug: simvastatin in addition to radiation therapy;   Radiation: radiation therapy
Outcome Measures: a- Response rate;   progression free and overall survival;   adverse effects

These studies may lead to new treatments and are adding insight into ZOCOR etiology and treatment.

A major focus of ZOCOR research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss ZOCOR